Endocrinology

Your Article Summary

See Latest Articles

Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA
Osteoporosis International, 10/06/09

Asche C et al. – Certain patient characteristics are predictors of physicians prescribing oral bisphosphonates. However, many patients remain untreated.

• Females age 50+ years with first fracture, osteoporosis diagnosis, or BMD ≤ 2.5 (index date) were identified in Geisinger Health System electronic health record database
• Treatment defined as oral bisphosphonate prescription order (risedronate sodium, ibandronate sodium, or alendronate) ≤ 90 days post-index date
• Treatment rates assessed and a multivariate logistic model used to identify predictors of treatment separately for patients with fracture (FRAC) and with diagnosis or low BMD (ICD-9-BMD)

• FRAC group had 2,003 female patients with a mean (SD) age of 69.0 (± 11.3) years and the ICD-9-BMD group had 12,976 female patients with a mean (SD) age of 66.9 (± 10.0) years
• Within 90 days of the index date of fracture, diagnosis, or low BMD score, 188 (9.4%) patients in FRAC group and 5,395 (41.6%) in ICD-9-BMD group received treatment
• Treatment positively associated with age and oral corticosteroids and negatively associated with BMI and subsequent BMD in both groups
• Smoking currently positively associated with treatment in ICD-9-BMD group

Today in Bone Metabolism...keeping you current

Receive free subspecialty "5-minute updates" via email

No anti-angiogenic effect of clinical dosing regimens of a single zoledronic acid injection in an experimental bone healing site
Bone , 12/11/09

The efficacy of calcitriol therapy in the management of bone loss and fractures: A qualitative review
Osteoporosis International, 12/10/09

Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: Systematic review and meta-analysis
Osteoporosis International, 12/10/09

 See all of Bone Metabolism